TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6783346

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as a micronized powder with lactose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as micropellets without lactose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as an aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30091001

Group type: EXPERIMENTAL
Intervention: Self-relevant information co-presented with target items during location judgment task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other-relevant information co-presented with target items during location judgment task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-relevant information co-presented with target items during color judgment task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other-relevant information co-presented with target items during color judgment task
Number of subjects: 0
Study: 28978349

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 90
Study: 26347103

Group type: EXPERIMENTAL
Intervention: Home parenteral nutrition (HPN)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Nomogram based on Cox proportional hazard regression modeling
Number of subjects: 579
Study: 23628668

Group type: EXPERIMENTAL
Intervention: Training group with sensor glove
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 14
Study: 21242686

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated polysulfone (Vit E PS) membrane
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-vitamin E-coated polysulfone (PS) membrane
Number of subjects: 62
Study: 19587626

Group type: EXPERIMENTAL
Intervention: US-guided tibial nerve block
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional landmark-based tibial nerve block
Number of subjects: 18
Study: 17877506

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance therapy options
Number of subjects: 0
Study: 16260856

Group type: EXPERIMENTAL
Intervention: Radiotherapy at the involved field, with 30 Gy delivered in 20 sessions
Number of subjects: 166

Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 166
Study: 12200755

Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 36
Study: 10404803

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg 4 times daily for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 23
Study: 7486110

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES; MW 200,000; substitution ratio 0.40‐0.55)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3% modified fluid gelatin (GEL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 42
Study: 2079844

Group type: EXPERIMENTAL
Intervention: Single Mode (SM) training program (walk/jog)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multimode (MM) training program (walk/jog, cycle, arm crank)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 479384

Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 mg morphine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30820560

Group type: EXPERIMENTAL
Intervention: Standard FET technique
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Elongated FET technique
Number of subjects: 26
Study: 28376815

Group type: EXPERIMENTAL
Intervention: EAMD
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PR-average
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PR-gaps
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: SR
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: TDM
Number of subjects: 230
Study: 26887207

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation (2 Hz, 3-5 mA) applied to bilateral LR 3, GB 34, TE 5, and LU 5 once every 12 hours for two days post-surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with filiform needles adhered to acupoints without electrical stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups received lower dose anesthetics (Fentanyl 250 μg + Flurbiprofen axetil 25 mg + normal saline 2 mL/h, Sauteralgyl if necessary)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 60
Study: 21949005

Group type: EXPERIMENTAL
Intervention: Target treatment group (2 hours of therapy and coaching each week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Community treatment group (variety of services averaging 3.9 hours per week)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Target treatment group
Number of subjects: 51
Study: 21300680

Group type: EXPERIMENTAL
Intervention: Adolescents born preterm
Number of subjects: 337

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 337
Study: 19702088

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) after surgical operation and chemotherapy (group C)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Chemotherapy (group B)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Surgery only (group A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (benign tumor, group D)
Number of subjects: 77
Study: 16763508

Group type: EXPERIMENTAL
Intervention: High cutoff hemofiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional hemofiltration
Number of subjects: 30
Study: 14561016

Group type: COMPARATOR
Intervention: Cardioselective beta-blockers (single dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cardioselective beta-blockers (longer duration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cardioselective beta-blockers
Number of subjects: 19
Study: 10898408

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg) plus ISMN (20 mg twice a day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg) plus GTN (500 microg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo plus ISMN (20 mg twice a day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo plus GTN (500 microg)
Number of subjects: 31
Study: 8599314

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (153 micromol or 10 mg Zn/d)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 1580300

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Favorable prognostic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HER-2/neu oncogene overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of low risk patients
Number of subjects: 0
Study: 2856902

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31113277

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (mean dose: 622.0 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 30592848

Group type: EXPERIMENTAL
Intervention: Specialized food product based on fermented milk whey (1.2×10^8 CFU/cm3) consumed for 21 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Specialized food product based on fermented milk whey
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (food starch of the same consistency)
Number of subjects: 30
Study: 27065001

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg once daily (up-titrated to 50 mg/day after 4 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 24766758

Group type: EXPERIMENTAL
Intervention: Enhanced supervision (EAA; group plus individual)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Common practice approach (CPA; group only)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EAA and CPA peer counselors
Number of subjects: 82
Study: 22476735

Group type: EXPERIMENTAL
Intervention: Urea supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentrate inclusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugarcane cultivar IAC‐862480 (CC1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugarcane cultivar IAC‐873184 (CC2)
Number of subjects: 0
Study: 20018326

Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30 kg/m²) in SISTEr trial
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30 kg/m²) in TOMUS trial
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Normal and overweight women (BMI < 30 kg/m²) in both trials
Number of subjects: 1252
Study: 17445921

Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (used by 109 patients, 58.9%)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-use of adjunctive corticosteroids
Number of subjects: 185
Study: 15993028

Group type: EXPERIMENTAL
Intervention: Completion axillary dissection (n=84)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Axillary sample with at least four nodes (n=81)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 165
Study: 12021644

Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (internally controlled)
Number of subjects: 0
Study: 10473741

Group type: EXPERIMENTAL
Intervention: Prehension task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip opening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapping and bimanual movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor function score (MOT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural tests
Number of subjects: 0
Study: 8732558

Group type: EXPERIMENTAL
Intervention: 20 kcal/ounce premature infant formula with iron
Number of subjects: 43

Group type: COMPARATOR
Intervention: 20 kcal/ounce standard cow's milk-based formula with iron
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mother's own milk with multivitamin supplement with iron
Number of subjects: 43
Study: 1656730

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alpha 1-antagonist (prazosin)
Number of subjects: 14
Study: 6613525

Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 1 g per day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 2 g per day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 3 g per day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29908417

Group type: EXPERIMENTAL
Intervention: Nilotinib (NIL) 800 mg/day (Cohort 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: High-dose imatinib (IM) 800 mg/day (Cohort 2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sustained standard-dose imatinib (IM) 400 mg/day (Cohort 3)
Number of subjects: 108
Study: 27502710

Group type: COMPARATOR
Intervention: Standard paclitaxel at 200 mg/m(2) (arm A)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: PK-guided dosing of paclitaxel (arm B)
Number of subjects: 365
Study: 24833327

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 600 mg bid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22547125

Group type: EXPERIMENTAL
Intervention: Acrylic single-piece IOL (ACR6D SE, Corneal, France)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acrylic three-piece IOL (AF-1 UV, Hoya, Japan)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acrylic single-piece IOL (ACR6D SE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acrylic three-piece IOL (AF-1 UV)
Number of subjects: 50
Study: 20658823

Group type: EXPERIMENTAL
Intervention: computer-generated tailored letters
Number of subjects: 1097

Group type: COMPARATOR
Intervention: assessment-only
Number of subjects: 1097
Study: 18813043

Group type: COMPARATOR
Intervention: Low-dose dexmedetomidine (loading, 3 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.2 microg x kg(‐1) x h(‐1) for 60 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose dexmedetomidine (loading, 6 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.4 microg x kg(‐1) x h(‐1) for 60 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15860765

Group type: EXPERIMENTAL
Intervention: Random-effects meta-analytic approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporating external estimates of intraclass correlation
Number of subjects: 0
Study: 11968583

Group type: EXPERIMENTAL
Intervention: Interferon alpha monotherapy (3 million u. three times per week until signs of relapse)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sequence administration of interferon alpha and dexamethasone (40 mg on days 1-4, 10-13, and 20-23, followed by interferon alpha after a four-week interval until disease progression)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Interferon alpha monotherapy or dexamethasone (preference question)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Maintenance treatment overall
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using EORTC QLQ-C30
Number of subjects: 83
Study: 10662395

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 704

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 704
Study: 7776148

Group type: EXPERIMENTAL
Intervention: Personal feedback of drinking relative to population norms
Number of subjects: 26

Group type: COMPARATOR
Intervention: No personal feedback
Number of subjects: 26
Study: 2181588

Group type: COMPARATOR
Intervention: Levodopa (mean dose: 485 ± 71 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean dose: 55 ± 6 mg daily)
Number of subjects: 36
Study: 394755

Group type: EXPERIMENTAL
Intervention: Aminophylline suppositories
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline tablets
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30821115

Group type: EXPERIMENTAL
Intervention: DP-VPA 1200 mg
Number of subjects: 12
Study: 28376214

Group type: EXPERIMENTAL
Intervention: Ki‐67
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: bcl2&bax
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Ki‐67 and bcl2&bax (jointly)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Base model
Number of subjects: 263
Study: 25678838

Group type: EXPERIMENTAL
Intervention: Local anesthetic only with lumbar interlaminar approach
Number of subjects: 240

Group type: COMPARATOR
Intervention: Local anesthetic only with caudal approach
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid with lumbar interlaminar approach
Number of subjects: 240

Group type: COMPARATOR
Intervention: Local anesthetic with steroid with caudal approach
Number of subjects: 240
Study: 23810548

Group type: EXPERIMENTAL
Intervention: Quinsy tonsillectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Interval tonsillectomy
Number of subjects: 34
Study: 21927793

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cyclophosphamide vs Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Changes in QLF
Number of subjects: 83
Study: 20204991

Group type: EXPERIMENTAL
Intervention: Brief self-management intervention emphasizing proactive coping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care controls
Number of subjects: 0
Study: 17298590

Group type: EXPERIMENTAL
Intervention: Self-management-oriented programme (treatment B)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Didactic‐oriented training programme (treatment A)
Number of subjects: 181

Group type: COMPARATOR
Intervention: More individualized approach (treatment C)
Number of subjects: 181
Study: 15075997

Group type: EXPERIMENTAL
Intervention: Tannenbaum-type Teflon-coated stents (TTC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Polyethylene stents (PE)
Number of subjects: 60
Study: 11233838

Group type: EXPERIMENTAL
Intervention: Group A (63 patients/95 hands) received 10 times 3 Gy (total: 30 Gy) in 2 series (each 5 times 3 Gy) separated by 8 weeks.
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Group B (66 patients/103 hands) received 7 times 3 Gy (total: 21 Gy) within 2 weeks.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 129
Study: 11220982

Group type: EXPERIMENTAL
Intervention: Sildenafil 10 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Sildenafil (all doses combined)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 8821690

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg every 28 days)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (300 mg/day)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Combination of goserelin acetate and cyproterone acetate
Number of subjects: 525

Group type: COMPARATOR
Intervention: Control (monotherapy)
Number of subjects: 525
Study: 1444298

Group type: EXPERIMENTAL
Intervention: Teicoplanin (100 mg twice a day for 10 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vancomycin (500 mg four times a day for 10 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 51
Study: 6085231

Group type: EXPERIMENTAL
Intervention: PA 109
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 31821361

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29074496

Group type: EXPERIMENTAL
Intervention: Primary medical management
Number of subjects: 440

Group type: COMPARATOR
Intervention: Augmented trabeculectomy
Number of subjects: 440
Study: 26879791

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Combined therapy (Finasteride + Tamsulosin)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Transurethral 2 micron laser resection of the prostate
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 790
Study: 24659740

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) treatment
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control arm (standard chemotherapy)
Number of subjects: 278
Study: 22167475

Group type: EXPERIMENTAL
Intervention: A‐weighted sound pressure level
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Psychoacoustic loudness (5th percentile)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Psychoacoustic annoyance (PA)
Number of subjects: 43
Study: 20454855

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) d,l-MPH 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) d,l-MPH 20 mg
Number of subjects: 8
Study: 17432644

Group type: EXPERIMENTAL
Intervention: Auricular point sticking combined with chiropractics
Number of subjects: 78

Group type: COMPARATOR
Intervention: Oral administration of pepsin mixture
Number of subjects: 78
Study: 16130060

Group type: COMPARATOR
Intervention: Epinephrine (0.03 microg/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milrinone (50 microg/kg followed by 0.5 microg/kg/min)
Number of subjects: 0
Study: 11851868

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg daily for 6 weeks, then increased to 0.4 mg if LDL-C did not decrease below 3.0 mmol x L(-1))
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg daily)
Number of subjects: 38
Study: 9861907

Group type: EXPERIMENTAL
Intervention: Early intervention program (early surgery, minimal narcotic analgesia, intense daily therapy, close monitoring)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care (routine hospital management)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 71
Study: 7595907

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.8 mg daily for 7 days (short protocol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fludrocortisone for 6 weeks (long protocol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (1.4 nmol/l) in vitro
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fludrocortisone treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Thrombin and vasopressin stimulation
Number of subjects: 16
Study: 2082005

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect (Korotkoff) method
Number of subjects: 0
Study: 31684841

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 146

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 146
Study: 30897090

Group type: COMPARATOR
Intervention: Continue cotrimoxazole (CTX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discontinue cotrimoxazole (STOP-CTX)
Number of subjects: 100
Study: 28634728

Group type: EXPERIMENTAL
Intervention: Lemon oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (control stimulus)
Number of subjects: 30
Study: 25466292

Group type: EXPERIMENTAL
Intervention: Pelvic compression belt (PCB)
Number of subjects: 50
Study: 23576531

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-obese participants
Number of subjects: 20